Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure BioSciences shares soar on shrinking debt and jump in first-quarter revenue

The life-sciences company saw a double-digit revenue increase for the period
test tubes
Pressure Biosciences' shares burst to the upside

Investors sent shares of Pressure BioSciences Inc (OTCMKTS:PBIO) soaring Tuesday after the life science group reported both a jump in first-quarter revenue thanks to an uptick in instrument sales, and said it has shrunk its debt.

By the afternoon, Pressure Bio's shares were up about 19% to US$3.90.

The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks partly to booming sales of the company’s laboratory instruments which utilize pressure to control bio-molecular interactions.

Sales of instruments jumped 8% to $420,089 in the first quarter compared with $396,095 last year while sales of related consumables rose 18% to $74,698 compared with $63,264 for the same period in 2017.

Pressure BioSciences also successfully converted US$6.39mln worth of debentures held by 22 debt holders into series AA preferred stock, which means that it paid off 92% of its 2015/2016 outstanding debenture debt on its balance sheet as of the end of last March.

If the company successfully persuades more debt holders to follow suit and swap their debt for equity, CEO Richard Schumacher says it would increase the company’s chance of uplisting to a national exchange such as the Nasdaq later this year.“We are in discussions with other note-holders about the possible conversion of debt into equity in the near future,” said Schumacher in a statement. “If some of these additional loans are also converted into equity, the projected balance sheet on June 30, 2018, will be materially stronger than the balance sheet as of March 31, 2018."

READ: Pressure Biosciences chief bullish on sale of new PreEMT platform

As a result of its move to pay down its debt and the bolstering of its revenue, the company’s loss shrank 24% to US$1.64 in the first quarter, down from a loss of US$2.16 in the year-ago quarter.

Among wins in the quarter is the signing of the first contract to evaluate the ability of the company’s patented PreEMT platform to improve the manufacturing process for protein therapeutic drug candidates.

Pressure BioSciences also entered a two-year global co-marketing and distribution agreement with ISS Inc, a supplier of high-pressure optical cell systems used for laboratory analysis. Working together, the two companies plan to replace ISS’s manual pressure generator with Pressure BioSciences’ computer-controlled, automated instruments.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing
1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use